The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

The following is a summary of “Role of glucocorticoid receptor expression in Chronic Chagas Cardiomyopathy: implications for ...

Dr Nwokwu further said that, in collaboration with the World Health Organisation (WHO), the Federal Ministry of Health has developed awareness materials on childhood cancer. These materials will be ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

The global immunohistochemistry (IHC) market is expected to grow from USD 3.5 billion in 2024 to USD 7.4 billion by 2034, reflecting a CAGR of 7.8% over the forecast period. Request a Sample Copy of ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

The brain tries to repair damage after a stroke by utilizing its own repair cells, which function like skilled craftsmen.

Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...

Kangkan Kalita is a reporter with The Times of India and covers issues on health, education, stories of human interest while ...

The following is a summary of “Expression and prognostic value of ferritinophagy-related NCOA4 gene in low-grade glioma: ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...